Day One Biopharmaceuticals, Inc. (ticker: DAWN) is an NASDAQ-listed pharmaceutical preparations company. DredgeCap's structured extraction of DAWN's SEC filings surfaces 3 active risk signals, including 2 delisting/deregistration signals, and 1 auditor-change signal. DAWN reported $158.18M in revenue and -$107.32B for the period ending 2025-12-31, with operating cash flow of -$103.76M. Cash and equivalents stood at $197.08M (up 57.7% year-over-year). Total assets of $507.83M exceed total liabilities of $66.67M. Each signal on this page is sourced verbatim from the underlying SEC filing. Use the tabs above to drill into auditor history, going-concern citations, dilution mechanics, cash runway, and the full risk-flag inventory.
DAWN SEC Filings
Full cached SEC EDGAR filing history for DAWN, grouped by form type and sorted newest-first within each group. 0 filings across 0 form types.
Filings sourced verbatim from SEC EDGAR submissions metadata. “Structured” links route to DredgeCap's per-filing renderer (XBRL-backed financials + cited highlights) when available; the EDGAR link always points to the canonical accession index on sec.gov.